(redirected from Rivastigmine tartrate)
Also found in: Medical.
Related to Rivastigmine tartrate: Fenofibrate, Exelon


A drug, C14H22N2O2, that inhibits the action of cholinesterase and is used to treat dementia in people with Alzheimer's disease and Parkinson's disease.

[riva-, of unknown origin + (physo)stigmine.]


n rivastigmina
References in periodicals archive ?
The most common antidementia prescriptions were donepezil hydrochloride (63.0%), memantine hydrochloride (41.8%), and rivastigmine tartrate (26.4%).
Aurobindo also received final approval for rivastigmine tartrate capsules USP, 1.5, 3, 4, 5 and 6 mg, the generic equivalent to Novartis Pharmaceuticals Corp.'s Exelon and for valganciclovir tablets USP, 450 mg, the generic equivalent to Valcyte (Hoffman-LaRoche Inc.)
All subjects were randomized to ginkgo biloba extract (EGb761, Willmar Schwabe Pharmaceutical Co., Karlsruhe, Germany), 120 mg and matching rivastigmine tartrate (Exelon, Novartis Pharms co., Basel, Switzerland) 4.5 mg.
Reddya[euro](tm)s Laboratories unveils Rivastigmine tartrate capsules in the US market(C)2011 M2 COMMUNICATIONS http://www.m2.com
Reddy's Laboratories (BOM:500124) said on Thursday it had introduced Rivastigmine Tartrate Capsules (1.5 mg, 3 mg, 4.5 mg and 6 mg), a bioequivalent generic version of Novartis' (VTX:NOVN) EXELON Capsules in the US on 15 September.
A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease.
The research shows that patients taking the Alzheimer's drug rivastigmine tartrate had significantly fewer dementia symptoms than those given a dummy placebo treatment.
Aurobindo Pharma is in receipt of final approval from the US Food & Drug Administration (USFDA) for production and marketing of Rivastigmine Tartrate Capsules USP, 1.5 mg, 3 mg, 4.5 mg and 6 mg.
In 2012 the company launched Rivastigmine Tartrate capsules, a generic version of Exelon by Novartis, after settling its Paragraph IV patent litigation, as well as Nevirapine tablets, a first-to-market generic version of Viramune by Boehringer Ingelheim, and Methscopolamine tablets, a generic version of Pamine and Pamiue Forte by Kenwood Therapeutics.